Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics, Inc. is trading at $135.07, down 0.01% on the session. The 50 day average sits at $134.13 and the 200 day at $91.97, which puts the stock in a uptrend. RSI is at 78.6, which reads as overbought, and MACD is bearish crossover. Volume is below average.

The nearest support is around $134.40 with resistance near $135.09, so that band frames the current range. Average daily movement is roughly $0.33, or about 0.2% of the share price, which is what any stop placement has to allow for. The overall health score of 78 out of 100 combines a trend score of 100, momentum of 43 and a risk score of 92.

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.